Subscribe Past Issues Ti

View this email in your browser



CSE: AIML

OTCQB: AIMLF

FWB: 42FB

The Pulse:

The Latest from AI/ML Innovations Inc.

17/07/25

In Case You Missed It:

- Neural Cloud's MaxYield platform for Cardiac Research
- Highlighting Medical Advisory Board member Dr. Brett Heilbron
- New Report Highlights Widespread AI Adoption in Healthcare
- Al Advancements Paving the Way for Early Disease Detection

Latest Advancements

Τı

Subscribe

Past Issues



MaxYield in Research

Cardiac Research.

MaxYield™ enhances cardiac research by ensuring rigorous data integrity protocols, with AI-driven signal clarity. By facilitating cross-disciplinary collaboration and offering continuous monitoring, MaxYield™ supports more reliable, high-quality research outcomes, supporting better patient care.

Must-Reads & Featured Articles

Behind The Innovation: Dr. Brett Heilbron


A UBC-trained cardiologist since 1995, has practiced in Vancouver since 1997. He is Level 3 Certified in Cardiac Computed Tomography, Medical Director of Electrodiagnostics at two Vancouver hospitals, a Clinical Associate Professor at UBC, and a Cardiology Consultant for Lifelabs British Columbia.



More on our Medical Advisors

Subscribe Past Issues Ti

Industry Watch



Read Full Article

KPMG report reveals AI's extensive adoption in healthcare

Healthcare organizations are rapidly adopting AI despite challenges. Top strategies include developing in-house AI capabilities (85%), using cloud-based platforms (69%), prioritizing generative AI and speech recognition, and increasing AI investment (77%).

Advancements in AI for Early Disease Detection

Wearable technology is revolutionizing health monitoring and disease detection.

These systems enable continuous monitoring of key health biomarkers, potentially transforming early disease detection and personalized medicine.



Read Full Article

Subscribe Past Issues Ti

About AI/ML Innovations Inc. (CSE:AIML|OTCQB:AIMLF|FWB:42FB)

AIML deploys advanced AI and neural-network signal-processing to turn noisy biometric data- starting with ECG - into diagnostic-grade insight. Our flagship MaxYield™ platform, now in FDA 510(k) review, powers wearables and remotemonitoring systems worldwide. With provisional patents filed for these innovations, we're setting the stage for next-gen ECG technologies. As we continue to expand our IP portfolio and refine our solutions, AIML remains committed to advancing healthcare with precision and speed, empowering better cardiac care worldwide.

Learn More







Copyright (C) 2025 AI/ML Innovations Inc.. All rights reserved.

Our mailing address is:

Want to change how you receive these emails?

You can update your preferences or unsubscribe